Allergy Therapeutics plc has reported an increase in half-year revenues.

The allergy immunotherapy specialist expects revenue for the six months ended 31st December 2025 to be £36.3 million (2024: £34), representing growth of 7%.

During the period, the group received marketing authorisation in Germany for Grassmuno, the first subcutaneous grass pollen immunotherapy approved under the TAV programme. Commercialisation commenced in January 2026 and sales momentum is expected to accelerate further in the second half of the financial year.